Knockdown of HnRNPA1 Promotes NSCLC Metastasis and EMT by Regulating Alternative Splicing of LAS1L Exon 9

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jul 11

PMID 35814393

Authors

Peng Han

Peng Cao

Jiaqi Yue

Kangle Kong

Shan Hu

Yu Deng

Lequn Li

Fan Li

Bo Zhao

Affiliations

Soon will be listed here.

Abstract

Tumor metastasis is still an insurmountable obstacle in tumor treatment. Lung cancer represents one of the most common malignancies with high morbidity worldwide. hnRNPA1 has been reported to be involved in the regulation of tumor metastasis, while its specific role in tumor metastasis seems to be controversial and its molecular mechanism in lung cancer metastasis remains to be further elucidated. In this study, we confirmed that knockdown of the hnRNPA1 led to enhanced migration, invasion and EMT transition in lung cancer cells. Bioinformatics analysis of the GSE34992 dataset revealed that hnRNPA1 may regulate the alternative splicing (AS) of LAS1L exon 9. Further AGE assays and RIP assays revealed that hnRNPA1 can directly bind to the LAS1L pre-mRNA to inhibit the splicing of LAS1L exon 9. The RNA pull-down assays showed that hnRNPA1 can specifically bind to the two sites (UAGGGU(WT1) and UGGGGU(WT3)) of LAS1L Intron 9. Further Transwell assays indicated that the expression ratio of LAS1L-L/LAS1L-S regulated by hnRNPA1 can further promote the migration, invasion and EMT transition in lung cancer cells. Moreover, hnRNPA1 expression showed significant heterogeneity in lung cancer tissues, which may contain new research directions and potential therapeutic targets. Our results indicate that hnRNPA1 can affect the metastasis of lung cancer cells by modulating the AS of LAS1L exon 9, highlighting the potential significance of hnRNPA1 in lung cancer metastasis.

Citing Articles

hnRNPA1 promotes the metastasis and proliferation of gastric cancer cells through WISP2-guided Wnt/β-catenin signaling pathway.

Jiang C, Xu D, Feng H, Ren Z, Li X, Chen Y Discov Oncol. 2024; 15(1):465.

PMID: 39298013 PMC: 11413309. DOI: 10.1007/s12672-024-01354-w.

MAGOH promotes gastric cancer progression via hnRNPA1 expression inhibition-mediated RONΔ160/PI3K/AKT signaling pathway activation.

Yu S, Chen C, Chen M, Liang J, Jiang K, Lou B J Exp Clin Cancer Res. 2024; 43(1):32.

PMID: 38268030 PMC: 10809607. DOI: 10.1186/s13046-024-02946-8.

whole-transcriptome analysis reveals a potential hsa_circ_0000375-miR-424-5p-TPM2/SRPX/SRGAP1 regulatory network related to liver metastasis of colorectal cancer.

Wei B, Xiao S, Lou W Heliyon. 2023; 9(11):e21688.

PMID: 37954397 PMC: 10638074. DOI: 10.1016/j.heliyon.2023.e21688.

M2 Macrophage-Derived Exosomal lncRNA MIR4435-2HG Promotes Progression of Infantile Hemangiomas by Targeting HNRNPA1.

Li Z, Cao Z, Li N, Wang L, Fu C, Huo R Int J Nanomedicine. 2023; 18:5943-5960.

PMID: 37881607 PMC: 10596068. DOI: 10.2147/IJN.S435132.

m6A reading protein RBMX as a biomarker for prognosis and tumor progression in esophageal cancer.

Tuersun H, Liu L, Zhang J, Maimaitizunong R, Tang X, Li H Transl Cancer Res. 2023; 12(9):2319-2335.

PMID: 37859733 PMC: 10583014. DOI: 10.21037/tcr-23-84.

References

Huelga S, Vu A, Arnold J, Liang T, Liu P, Yan B . Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep. 2012; 1(2):167-78. PMC: 3345519. DOI: 10.1016/j.celrep.2012.02.001. View

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View

Bonnal S, Lopez-Oreja I, Valcarcel J . Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020; 17(8):457-474. DOI: 10.1038/s41571-020-0350-x. View

Kahles A, Lehmann K, Toussaint N, Huser M, Stark S, Sachsenberg T . Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell. 2018; 34(2):211-224.e6. PMC: 9844097. DOI: 10.1016/j.ccell.2018.07.001. View

Ryan M, Wong W, Brown R, Akbani R, Su X, Broom B . TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res. 2015; 44(D1):D1018-22. PMC: 4702910. DOI: 10.1093/nar/gkv1288. View

Fanis P, Gillemans N, Aghajanirefah A, Pourfarzad F, Demmers J, Esteghamat F . Five friends of methylated chromatin target of protein-arginine-methyltransferase[prmt]-1 (chtop), a complex linking arginine methylation to desumoylation. Mol Cell Proteomics. 2012; 11(11):1263-73. PMC: 3494204. DOI: 10.1074/mcp.M112.017194. View

Zheng H, Chen C, Luo Y, Yu M, He W, An M . Tumor-derived exosomal BCYRN1 activates WNT5A/VEGF-C/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer. Clin Transl Med. 2021; 11(7):e497. PMC: 8288020. DOI: 10.1002/ctm2.497. View

David C, Chen M, Assanah M, Canoll P, Manley J . HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2009; 463(7279):364-8. PMC: 2950088. DOI: 10.1038/nature08697. View

Lee Y, Rio D . Mechanisms and Regulation of Alternative Pre-mRNA Splicing. Annu Rev Biochem. 2015; 84:291-323. PMC: 4526142. DOI: 10.1146/annurev-biochem-060614-034316. View

10.

Chabot B, Blanchette M, Lapierre I, La Branche H . An intron element modulating 5' splice site selection in the hnRNP A1 pre-mRNA interacts with hnRNP A1. Mol Cell Biol. 1997; 17(4):1776-86. PMC: 232024. DOI: 10.1128/MCB.17.4.1776. View

11.

Catez F, Dalla Venezia N, Marcel V, Zorbas C, Lafontaine D, Diaz J . Ribosome biogenesis: An emerging druggable pathway for cancer therapeutics. Biochem Pharmacol. 2018; 159:74-81. DOI: 10.1016/j.bcp.2018.11.014. View

12.

Liu S, Cheng C . Alternative RNA splicing and cancer. Wiley Interdiscip Rev RNA. 2013; 4(5):547-66. PMC: 4426271. DOI: 10.1002/wrna.1178. View

13.

Kedzierska H, Piekielko-Witkowska A . Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer. Cancer Lett. 2017; 396:53-65. DOI: 10.1016/j.canlet.2017.03.013. View

14.

Hutchison S, Lebel C, Blanchette M, Chabot B . Distinct sets of adjacent heterogeneous nuclear ribonucleoprotein (hnRNP) A1/A2 binding sites control 5' splice site selection in the hnRNP A1 mRNA precursor. J Biol Chem. 2002; 277(33):29745-52. DOI: 10.1074/jbc.M203633200. View

15.

Weeks S, Kammerud S, Metge B, AlSheikh H, Schneider D, Chen D . Inhibiting β-catenin disables nucleolar functions in triple-negative breast cancer. Cell Death Dis. 2021; 12(3):242. PMC: 7933177. DOI: 10.1038/s41419-021-03531-z. View

16.

Puppo M, Bucci G, Rossi M, Giovarelli M, Bordo D, Moshiri A . miRNA-Mediated KHSRP Silencing Rewires Distinct Post-transcriptional Programs during TGF-β-Induced Epithelial-to-Mesenchymal Transition. Cell Rep. 2016; 16(4):967-978. DOI: 10.1016/j.celrep.2016.06.055. View

17.

Wen Z, Lian L, Ding H, Hu Y, Xiao Z, Xiong K . LncRNA ANCR promotes hepatocellular carcinoma metastasis through upregulating HNRNPA1 expression. RNA Biol. 2019; 17(3):381-394. PMC: 6999620. DOI: 10.1080/15476286.2019.1708547. View

18.

Han K, Yeo G, An P, Burge C, Grabowski P . A combinatorial code for splicing silencing: UAGG and GGGG motifs. PLoS Biol. 2005; 3(5):e158. PMC: 1079783. DOI: 10.1371/journal.pbio.0030158. View

19.

Okunola H, Krainer A . Cooperative-binding and splicing-repressive properties of hnRNP A1. Mol Cell Biol. 2009; 29(20):5620-31. PMC: 2756886. DOI: 10.1128/MCB.01678-08. View

20.

Han S, Tang Y, Smith R . Functional diversity of the hnRNPs: past, present and perspectives. Biochem J. 2010; 430(3):379-92. DOI: 10.1042/BJ20100396. View